Effects of an Intensified Treatment With ACE-I,ATA II and Statins in Alport Syndrome
Alport Syndrome
About this trial
This is an interventional treatment trial for Alport Syndrome
Eligibility Criteria
Inclusion Criteria: age ≥15 years Alport disease Creatinine clearance >20 ml/min/1.73 mq with variation of less than 30% in the three months prior to study entry written informed consent. For patients <18 years old a written informed consent of both parents is needed Exclusion Criteria: treatment with immunosuppressive drugs in the six months preceding the study vascular disease of the kidney obstructive uropathy, prostatic hypertrophy, incomplete bladder emptying transplanted kidney clinically relevant electrolyte imbalance (e.g., hyperkaliemia with serum K+ > 5.5 mEq/l) any concomitant medication with drugs that may directly affect UAE including ACE-inhibitors, angiotensin II receptor antagonists, non dihydropyridine CCBS, HMGCoA reductase inhibitors in the last one month history of hypersensitivity to the study drugs impossibility to temporary withdrawn ACE-I or ATA II or statins (heart failure, cardiovascular events over the last three months) any clinically relevant condition that may affect study participation and/or study results pregnancy, ineffective contraception, breast feeding inability to fully understand the purposes/risks of the study and/or to provide a written informed consent
Sites / Locations
- Clinical Research Center for Rare Diseases
Arms of the Study
Arm 1
Experimental
ACE inhibitor, ATA II antagonists and Statins